Apremilast: a possible alternative to local treatment of Beceht's disease
DOI:
https://doi.org/10.700991/BJ/2024.01.01.26Keywords:
Behcet's disease, Inflammatory disease, Ulcers, Apremilast, OdontologyAbstract
This letter aims to raise awareness about Behcet's disease (BD) and its impact, particularly in Honduras. BD is a chronic inflammatory disease that affects different organs. It is recurrent and of unknown origin. It is characterized by neurological, ocular, vascular, gastrointestinal, and mucocutaneous alterations that could be fatal1. Among the mucocutaneous manifestations, we can mention oral ulcers, also known as thrush, which are usually painful and harm the quality of life of people who suffer from them. These mouth ulcers begin as lesions of oral mucosa, gums, tongue, or lips. They are characterized by being rounded and raised and quickly transform into painful ulcers. The sores heal in one to three weeks, although they reappear. The cause of BD is unknown. It is believed that there could be a genetic predisposition that has been demonstrated by its association with HLA genes (HLA B51/B5, MICA gene) and other non-HLA genes (1-ICAM gene, TNF gene, MEFV gene) and also requires other factors such as the participation of microorganisms such as streptococci, mycobacteria and Helicobacter pylori.
References
1. Yurdakumul,S., Hamuryudan, V., Yazia, H. Behçet sindrome. Curr Opin Rheumatol, 2004, pp. 16
2. Davatchi F, Chams-Davatchi C, Shahram F, et al. Pathergy test in Behcet's disease: change in incidence over the time. APLAR J Rheumatol. 2007;10:333– 335.
3. Enfermedad de Behcet. Disponible en: https://www.mayoclinic.org/es/diseases-conditions/behcets-disease/symptoms-causes/syc-20351326 (accedido en 05 de enero de 2024).
4. Ahmad,T., Wallace, G.R, James, T et al. Mapping the HLA association in Behçet's disease: a role for tumor necrosis factor polymorphisms?. Arthritis Rheum, 2003, 48, pp. 807
5. García-Palenzuela,R., Graña Gil.,Varela Arias, M., Tovar Bobo, M. Actualización de la enfermedad de Behçet. A propósito de 2 casos en atención primaria, Medicina de Familia. SEMERGEN, 2012, 38:1, pg 33-39
6. Yazici H, Seyahi E, Hatemi G, Yazici Y. Behçet syndrome: a contemporary view. Nat Rev Rheumatol. 2018;14(2):107-119.
7. Adherencia a los tratamientos a largo plazo, pruebas para la acción. Disponible en: https://www3.paho.org/hq/dmdocuments/2012/WHO-Adherence-Long-Term-Therapies-Spa-2003.pdf (accedido en 05 de enero 2024).
8. Sarango-Granda, P.; Espinoza, L.C.; Díaz-Garrido, N.; Alvarado, H.; Rodríguez-Lagunas, M.J.; Baldomá, L.; Calpena, A. Effect of Penetration Enhancers and Safety on the Transdermal Delivery of Apremilast in Skin. Pharmaceutics 2022, 14, 1011.
9. Silva-Abreu M, Sosa L, Espinoza LC, Fábrega MJ, Rodríguez-Lagunas MJ, Mallandrich M, Calpena AC, Garduño-Ramírez ML, Rincón M. Efficacy of Apremilast Gels in Mouse Model of Imiquimod-Induced Psoriasis Skin Inflammation. Pharmaceutics. 2023 Sep 29;15(10):2403.
Published
How to Cite
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with BioNatura Journal agree to the following terms: Authors retain copyright and grant the BioNatura Institutional Publishing Consortium (BIPC) right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). This allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
